Meeting
2024 ASCO Annual Meeting
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
Authors
Stephen J. Freedland
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Medical Center, Los Angeles, CA
Stephen J. Freedland , John Mulhall , Martin Gleave , Ugo De Giorgi , Antti Rannikko , Fred Saad , Miguel Ramirez-Backhaus , Jasmina I. Ivanova , Anchen F. Nasr , Arijit Ganguli , Pavol Kral , Arlene Reisman , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT02319837
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5084)
DOI
10.1200/JCO.2024.42.16_suppl.5084
Abstract #
5084
Poster Bd #
490
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.
First Author: Stephen J. Freedland
Poster
2024 ASCO Genitourinary Cancers Symposium
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.
First Author: Stephen J. Freedland
Poster
2023 ASCO Annual Meeting
PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.
First Author: Wesley Robert Armstrong
Poster
2024 ASCO Genitourinary Cancers Symposium
Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza).
First Author: Sara Bleve